 |
|
Stock Charts
| |||||
|
|
|
(ALKS) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 19, 2013
(Stock Blog Hub,
5/2/13)
Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the...(read more)
(Stock Blog Hub,
2/11/13)
Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) pursuant to Rule 144 under the US Securities Act of...(read more)
(Phil’s Stock World,
1/11/12)
Courtesy of Benzinga. A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating...(read more)
Alkermes (ALKS) Company Overview
Alkermes, Inc. (ALKS) is an emerging pharmaceutical company engaged in the development and commercialization of therapeutic products that utilize its Proprietary Drug Delivery Technologies. The company uses its ProLease and Medisorb delivery systems to develop controlled and extended release versions of injectable drugs. It also utilizes its proprietary AIR pulmonary delivery system for the development of inhalers. Its lead commercial product, Risperdal Consta (or simply Consta), was developed using the Medisorb delivery system for the treatment of schizophrenia and is marketed worldwide by Johnson & Johnson. In April, 2006, the company received FDA approval of Vivitrol for the treatment of alcohol dependence. Vivitrol was launched in June 2006 and is marketed by Cephalon. The company is also developing AIR Insulin for type I diabetes, and Byetta (formerly Exenatide) LAR for type II diabetes. Alkermes is headquartered in Cambridge, MA. (Read more at Wikinvest ) |
|
||||||
